IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation

Journal of Cellular Biochemistry

Volumn 113, Issue 5, 2012, Pages 1569-1580

  Roca, Hernan ^a   Craig, Matthew J ^b   Ying, Chi ^b   Varsos, Zachary S ^b   Czarnieski, Paul ^b   Alva, Ajjai S ^b   Hernandez, James ^b   Fuller, David ^b   Daignault, Stephanie ^c   Healy, Patrick N ^c   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

IL 4; JNK; NUTRIENT DEPLETION STRESS; PROLIFERATION; PROSTATE CANCER; SURVIVIN

Indexed keywords

INTERLEUKIN 4; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUTRIENT; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-4; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; STRESS, PHYSIOLOGICAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84859037244     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24025     Document Type: Article

References (50)

1. Altieri DC,. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nature reviews. Cancer 8: 61-70.
2. Arguello F, Baggs RB, Frantz CN,. 1988. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876-6881. (Pubitemid 19012221)
3. Chang TL, Peng X, Fu XY,. 2000. Interleukin-4 mediates cell growth inhibition through activation of Stat1. J Biol Chem 275: 10212-10217. (Pubitemid 30202077)
4. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME,. 2010. CD95 promotes tumour growth. Nature 465: 492-496.
5. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, Messina A, Peschle C, De Maria R,. 2004. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 172: 5467-5477. (Pubitemid 38542047)
6. Davis RJ,. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
7. Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I,. 2010. Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors. Ann Hematol 89: 1125-1132.
8. Di Stefano AB, Iovino F, Lombardo Y, Eterno V, Hoger T, Dieli F, Stassi G, Todaro M,. 2010. Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol 225: 555-561.
9. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z,. 2003. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102: 630-637. (Pubitemid 36841985)
10. Ferte C, Andre F, Soria JC,. 2010. Molecular circuits of solid tumors: Prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 7: 367-380.
11. Fukushi J, Ono M, Morikawa W, Iwamoto Y, Kuwano M,. 2000. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol 165: 2818-2823. (Pubitemid 30660733)
12. Glinsky GV, Berezovska O, Glinskii AB,. 2005. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521. (Pubitemid 40814659)
13. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA,. 2010. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24: 241-255.
14. Gooch JL, Christy B, Yee D,. 2002. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 4: 324-331. (Pubitemid 34755842)
15. Gooch JL, Lee AV, Yee D,. 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58: 4199-4205. (Pubitemid 28440580)
16. Gordon S,. 2003. Alternative activation of macrophages. Nature reviews. Immunology 3: 23-35. (Pubitemid 37328697)
17. Gordon S, Martinez FO,. 2010. Alternative activation of macrophages: Mechanism and functions. Immunity 32: 593-604.
18. Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC,. 2009. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 69: 4954-4958.
19. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF,. 2007. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39: 741-749. (Pubitemid 46848584)
20. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR,. 2003. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6cells in murine models of human prostate cancer. Clin Exp Metastasis 20: 745-756. (Pubitemid 38019276)
21. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E,. 2007. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 131: 271-285. (Pubitemid 47576137)
22. Jochum W, Passegue E, Wagner EF,. 2001. AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412. (Pubitemid 32531298)
23. Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, Husain SR, Puri RK,. 2002. Interleukin 4 receptor on human lung cancer: A molecular target for cytotoxin therapy. Clin Cancer Res (An official journal of the American Association for Cancer Research) 8: 3503-3511. (Pubitemid 35340728)
24. Kennedy NJ, Davis RJ,. 2003. Role of JNK in tumor development. Cell Cycle 2: 199-201.
25. Koller FL, Hwang DG, Dozier EA, Fingleton B,. 2010. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 31: 1010-1017.
26. Li Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C, Lu Y, Qin Z,. 2008. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68: 8687-8694.
27. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ,. 2006. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78.
28. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ,. 2007. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67: 9417-9424. (Pubitemid 47535932)
29. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z,. 2007. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11: 447-460. (Pubitemid 46670078)
30. Mantovani A, Allavena P, Sica A, Balkwill F,. 2008. Cancer-related inflammation. Nature 454: 436-444.
31. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S,. 2002. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622. (Pubitemid 34478319)
32. Mizushima N, Yoshimori T,. 2007. How to interpret LC3 immunoblotting. Autophagy 3: 542-545. (Pubitemid 350060049)
33. Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL,. 1996. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res (An official journal of the American Association for Cancer Research) 2: 127-135. (Pubitemid 26042187)
34. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M,. 2005. Interleukin-4 enhances proliferation of human pancreatic cancer cells: Evidence for autocrine and paracrine actions. Br J Cancer 92: 921-928. (Pubitemid 40462640)
35. Roca H, Varsos Z, Pienta KJ,. 2008a. CCL2 protects prostate cancer PC3cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 283: 25057-25073.
36. Roca H, Varsos ZS, Mizutani K, Pienta KJ,. 2008b. CCL2, survivin and autophagy: New links with implications in human cancer. Autophagy 4: 969-971.
37. Roca H, Varsos ZS, Pienta KJ,. 2009. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3cells. Neoplasia 11: 1309-1317.
38. Shaulian E, Karin M,. 2002. AP-1 as a regulator of cell life and death. Nature Cell Biol 4: E131-136. (Pubitemid 34521026)
39. Sokol CL, Barton GM, Farr AG, Medzhitov R,. 2008. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nature Immunol 9: 310-318. (Pubitemid 351267328)
40. Stremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK,. 1999. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med 189: 919-930. (Pubitemid 29149348)
41. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G,. 2007. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402. (Pubitemid 47506537)
42. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesu G, De Maria R, Stassi G,. 2006. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 66: 1491-1499. (Pubitemid 43259930)
43. Topp MS, Papadimitriou CA, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, Oberberg D, Reufi B, Stein H, Thiel E, et al. 1995. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 55: 2173-2176.
44. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC,. 2007. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684. (Pubitemid 46663841)
45. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL,. 2007. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555-569. (Pubitemid 46856910)
46. Wagner EF, Nebreda AR,. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nature reviews. Cancer 9: 537-549.
47. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D,. 2002. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13: 1977-2000. (Pubitemid 34651487)
48. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM,. 2011. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332: 243-247.
49. Yoshimoto T, Yasuda K, Tanaka H, Nakahira M, Imai Y, Fujimori Y, Nakanishi K,. 2009. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 10: 706-712.
50. Yu SJ, Kim HS, Cho SW, Sohn J,. 2004. IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp Mol Med 36: 372-379. (Pubitemid 39279534)